智通财经APP获悉，先声药业(02096)早盘涨超7%，截至发稿，涨6.54%，报9.29港元，成交额1.04亿港元。
消息面上，据香港电台网站5月17日消息，香港新冠病毒活跃程度处于高水平，儿童及成人严重个案的数字亦录得升幅。另外，中国疾控中心在5月8日发布的2025年4月全国急性呼吸道传染病哨点监测情况显示，4月14日-5月4日连续三周内，新型冠状病毒成门急诊流感样病例就诊量的首位。
据悉，先声药业的先诺欣®是国内首款获得常规批准的口服抗新冠病毒药物。先诺欣是由先声药业与中科院上海药物研究所、武汉病毒研究所联合研发，具备自主知识产权的国产首款3CL靶点抗新冠创新药，于2023年1月28日附条件批准在国内上市，此后也被国家纳入医保报销目录。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.